Heron Therapeutics HRTX Estimates

NASDAQ HRTX
$0.34 -0.01 (-3.54%)
As of: Sep 9, 2026 · 3:59 PM EDT
Analyst Estimates

Heron Therapeutics, Inc. /De/ Revenue Estimates

Periods 26
Next Period Q3 26
Consensus 35.32 M

Analysts expect Heron Therapeutics, Inc. /De/ to report revenue of 35.32 M for Q3 26, against a range of 33.50 M to 37.14 M. The most recent reported quarter, Q2 26, came in at 37.67 M, a 7.9% miss against the 40.92 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 32.81 M40.78 M38.90 M37.20 M38.21 M40.59 M34.71 M37.67 M--------
High Estimate 36.29 M40.94 M42.09 M38.66 M39.50 M45.21 M41.82 M43.02 M37.14 M37.19 M36.66 M38.64 M41.15 M43.08 M37.18 M44.94 M
Low Estimate 33.47 M38.30 M37.73 M35.90 M36.52 M38.44 M35.46 M38.82 M33.50 M34.85 M33.19 M35.79 M35.90 M38.41 M33.41 M37.56 M
Consensus Estimate 34.88 M39.62 M39.91 M37.28 M38.01 M41.82 M38.64 M40.92 M35.32 M36.02 M34.92 M37.22 M38.53 M40.75 M35.29 M41.25 M
Analyst Estimates

Heron Therapeutics, Inc. /De/ Earnings Per Share (EPS) Estimates

Periods 26
Next Period Q3 26
Consensus -0.03

Analysts expect Heron Therapeutics, Inc. /De/ to report earnings per share of -0.03 for Q3 26, against a range of -0.03 to -0.03. The most recent reported quarter, Q2 26, came in at -0.03, a 200.0% miss against the -0.01 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -0.030.020.01-0.02-0.10-0.02-0.04-0.03--------
High Estimate -0.04-0.03-0.01-0.01-0.01-0.02-0.02-0.01-0.03-0.03-0.04-0.03-0.04-0.01-0.02-0.02
Low Estimate -0.04-0.03-0.01-0.01-0.01-0.02-0.02-0.01-0.03-0.03-0.04-0.03-0.04-0.01-0.02-0.02
Consensus Estimate -0.04-0.03-0.01-0.01-0.01-0.02-0.02-0.01-0.03-0.03-0.04-0.03-0.04-0.01-0.02-0.02